Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature

Author(s): Ichrak B. Abdallah*, Sonia Ben Nasr, Chadia Chourabi, Aref Zribi, Mehdi Balti, Wafa Fehri and Abderrazek Haddaoui

Volume 17, Issue 1, 2022

Published on: 11 August, 2021

Page: [70 - 74] Pages: 5

DOI: 10.2174/1574886316666210811155102

Price: $65

Abstract

Introduction: Gemcitabine is a commonly used antimetabolite that has been effective in a broad spec- trum of tumors so far. The main grade three and four known toxicity of this drug is myelosuppres- sion. Cardiac adverse events have been rarely reported and gemcitabine-induced Atrial-Fibrillation (AF) has been described in only five previous cases so far. Here we report the 6th case of gemc- itabine-related AF.

Case Presentation: A 68-year-old man diagnosed with metastatic nasopharyngeal cancer was referred to our oncology department. He started first-line chemotherapy with gemcitabine and cisplatin. He presented poorly tolerated atrial fibrillation related to gemcitabine infusion that lasted for six days. The treatment was then withdrawn, and the patient received the best supportive care.

Conclusion: We conclude that medical oncologists and cardiologists should be aware of such toxicities of gemc- itabine, especially in the elderly who seem to be at a higher risk of such adverse events and which may dictate discontinuation of the drug.

Keywords: Gemcitabine, arrhythmia, atrial fibrillation, antimetabolites, chemotherapy, cisplatin.

« Previous Next »
[1]
Tavil Y, Arslan U, Okyay K, Sen N, Boyaci B. Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man. Onkologie 2007; 30(5): 253-5.
[PMID: 17460420]
[2]
Zhang Y, Chen L, Hu G-Q, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019; 381(12): 1124-35.
[http://dx.doi.org/10.1056/NEJMoa1905287] [PMID: 31150573]
[3]
Ciotti R, Belotti G, Facchi E, Cantù A, D’Amico A, Gatti C. Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine. Ann Oncol 1999; 10: 997.
[http://dx.doi.org/10.1023/A:1008305716918]
[4]
Santini D, Tonini G, Abbate A, et al. Gemcitabine-induced atrial fibrillation: A hitherto unreported manifestation of drug toxicity. Ann Oncol 2000; 11(4): 479-81.
[http://dx.doi.org/10.1023/A:1008380208045] [PMID: 10847470]
[5]
Ferrari D, Carbone C, Codec C. Gemcitabine and atrial fibrillation: A rare manifestation of chemotherapy toxicity: Anticancer. Drugs 2006; 17: 359-61.
[6]
Khan MF, Gottesman S, Boyella R, Juneman E. Gemcitabine-induced cardiomyopathy: A case report and review of the literature. J Med Case Reports 2014; 8: 220.
[http://dx.doi.org/10.1186/1752-1947-8-220] [PMID: 24957905]
[7]
Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem J-E. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacol Ther 2018; 189: 89-103.
[8]
Qanungo S, Uys JD, Manevich Y, et al. N-acetyl-l- cysteine sensitizes pancreatic cancers to gemcitabine by targeting the NFκB pathway. Biomed Pharmacother 2014; 68: 855-64.
[9]
Anon. . Gemzar (Gemcitabine Hcl): Uses, dosage, side effects, interactions, warning. RxList
[10]
Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: An EORTC-PAMM perspective. Cancer Chemother Pharmacol 2016; 78(1): 1-12.
[http://dx.doi.org/10.1007/s00280-016-3003-0] [PMID: 27007129]
[11]
Mynhardt C, Damelin LH, Jivan R, et al. Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. J Cell Biochem 2018; 119(1): 1193-203.
[http://dx.doi.org/10.1002/jcb.26291] [PMID: 28722177]
[12]
Li X, Li T, Liu Z, Gou S, Wang C. The effect of metformin on survival of patients with pancreatic cancer: A meta-analysis. Sci Rep 2017; 7(1): 5825.
[http://dx.doi.org/10.1038/s41598-017-06207-x] [PMID: 28724893]

Rights & Permissions Print Cite
Article Metrics
30
1
© 2024 Bentham Science Publishers | Privacy Policy